#ESMO26 💉 AMPLIFY-7P | Phase II
👥 144 pts | Resected PDAC
💊 Camupepimut (KRAS vaccine) vs observation
❌ Primary DFS endpoint not met:
23.8 vs 21.2 mo (HR 0.85; p=0.53)
🔬 Exploratory findings:
🧬 ctDNA+ predicts poor DFS (HR 6.56)
📈 No prior RT: DFS 23.8 vs 10.4 mo
💡 Signals warrant further investigation.
@OncoAlert
423 浏览 · 5 赞 · 5 转发 · 0 回复
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Nieves Martinez Lago MD PhD · x.com